INSYS Therapeutics Announces NDA Acceptance of its Fentanyl SL Spray
Insys Therapeutics, Inc. (formerly NeoPharm, Inc.) (Other OTC:NEOL.PK) today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.